SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

83.8 0.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

82.35

Max

83.9

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

34.873

66.418

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+4.08% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

233M

4.2B

Ouverture précédente

83.38

Clôture précédente

83.8

Sentiment de l'Actualité

By Acuity

50%

50%

148 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 avr. 2026, 23:44 UTC

Market Talk
Principaux Événements d'Actualité

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12 avr. 2026, 23:38 UTC

Market Talk
Principaux Événements d'Actualité

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12 avr. 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12 avr. 2026, 23:36 UTC

Market Talk
Principaux Événements d'Actualité

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12 avr. 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12 avr. 2026, 23:09 UTC

Market Talk
Principaux Événements d'Actualité

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12 avr. 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 avr. 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12 avr. 2026, 22:56 UTC

Principaux Événements d'Actualité

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12 avr. 2026, 22:54 UTC

Principaux Événements d'Actualité

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12 avr. 2026, 22:53 UTC

Principaux Événements d'Actualité

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12 avr. 2026, 22:51 UTC

Principaux Événements d'Actualité

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12 avr. 2026, 22:50 UTC

Market Talk
Principaux Événements d'Actualité

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12 avr. 2026, 22:37 UTC

Market Talk
Principaux Événements d'Actualité

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11 avr. 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11 avr. 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11 avr. 2026, 08:20 UTC

Market Talk
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

11 avr. 2026, 00:00 UTC

Résultats
Acquisitions, Fusions, Rachats

Big Yachts, Big Bucks -- Barrons.com

10 avr. 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 avr. 2026, 21:01 UTC

Résultats

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 avr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

10 avr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 avr. 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 avr. 2026, 20:10 UTC

Acquisitions, Fusions, Rachats

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 avr. 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 avr. 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 avr. 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 avr. 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 avr. 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

4.08% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  4.08%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

148 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat